Golotimod
Based on 1 Customer Validation
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
For research use only. We do not sell to patients.
- Purity: 98.98%
- CAS No.: 229305-39-9
- Formula: C16H19N3O5
- Molecular Weight:333.34
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Antibacterial Compound Library
HY-L049
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Peptide Library
HY-L105
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Anti-tuberculosis Compound Library
HY-L142
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Macrophage Related Compound Library
HY-L174
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
Non-natural Amino Acid Compound Library
HY-L198
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
-
Lactylation Compound Library
HY-L249
Biological Activity
|
STAT3 |
Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Hartley guinea pigs (250-300 g) infected HSV-2[1]
-
Dosage:100 μg/kg
-
Administration:Oral gavage or subcutaneous injection; 5 days
-
Result:Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07.
-
Animal Model:Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis[3]
-
Dosage:10, 100 μg/kg or 1 mg/kg
-
Administration:Subcutaneous injection; once or twice a day from days 1 to 20
-
Result:Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg.
Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.
Chemical Information
-
CAS No. 229305-39-9
-
Appearance Solid
-
Molecular Weight 333.34
-
Formula C16H19N3O5
-
Color White to off-white
-
Synonyms
SCV 07; Gamma-D-glutamyl-L-tryptophan
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
H2O : 125 mg/mL (374.99 mM; Need ultrasonic)
DMSO : 50 mg/mL (150.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents. 2008 Sep;32(3):262-6. [Content Brief]
[2]. Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92. [Content Brief]
[3]. Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis. 2010 Oct;16(7):655-60. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.9999 mL | 14.9997 mL | 29.9994 mL | 74.9985 mL |
| 5 mM | 0.6000 mL | 2.9999 mL | 5.9999 mL | 14.9997 mL | |
| 10 mM | 0.3000 mL | 1.5000 mL | 2.9999 mL | 7.4999 mL | |
| 15 mM | 0.2000 mL | 1.0000 mL | 2.0000 mL | 4.9999 mL | |
| 20 mM | 0.1500 mL | 0.7500 mL | 1.5000 mL | 3.7499 mL | |
| 25 mM | 0.1200 mL | 0.6000 mL | 1.2000 mL | 2.9999 mL | |
| 30 mM | 0.1000 mL | 0.5000 mL | 1.0000 mL | 2.5000 mL | |
| 40 mM | 0.0750 mL | 0.3750 mL | 0.7500 mL | 1.8750 mL | |
| 50 mM | 0.0600 mL | 0.3000 mL | 0.6000 mL | 1.5000 mL | |
| 60 mM | 0.0500 mL | 0.2500 mL | 0.5000 mL | 1.2500 mL | |
| 80 mM | 0.0375 mL | 0.1875 mL | 0.3750 mL | 0.9375 mL | |
| 100 mM | 0.0300 mL | 0.1500 mL | 0.3000 mL | 0.7500 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz